TRIAMTERENE AND HYDROCHLOROTHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Triamterene And Hydrochlorothiazide, and what generic alternatives are available?
Triamterene And Hydrochlorothiazide is a drug marketed by Ani Pharms, Cadila, Chartwell Rx, Duramed Pharms Barr, Lannett Co Inc, Norvium Bioscience, Novartis, Sandoz, Vitarine, Am Therap, Apotex Inc, Pliva, Quantum Pharmics, Rubicon, Watson Labs, and Zydus Pharms. and is included in twenty-two NDAs.
The generic ingredient in TRIAMTERENE AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; triamterene. There are thirty-two drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; triamterene profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRIAMTERENE AND HYDROCHLOROTHIAZIDE?
- What are the global sales for TRIAMTERENE AND HYDROCHLOROTHIAZIDE?
- What is Average Wholesale Price for TRIAMTERENE AND HYDROCHLOROTHIAZIDE?
Summary for TRIAMTERENE AND HYDROCHLOROTHIAZIDE
| US Patents: | 0 |
| Applicants: | 16 |
| NDAs: | 22 |
| Finished Product Suppliers / Packagers: | 29 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Clinical Trials: | 5 |
| Patent Applications: | 107 |
| What excipients (inactive ingredients) are in TRIAMTERENE AND HYDROCHLOROTHIAZIDE? | TRIAMTERENE AND HYDROCHLOROTHIAZIDE excipients list |
| DailyMed Link: | TRIAMTERENE AND HYDROCHLOROTHIAZIDE at DailyMed |
Recent Clinical Trials for TRIAMTERENE AND HYDROCHLOROTHIAZIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, Irvine | Phase 4 |
| West China Hospital | Phase 4 |
| Vanderbilt University | N/A |
Pharmacology for TRIAMTERENE AND HYDROCHLOROTHIAZIDE
| Drug Class | Potassium-sparing Diuretic Thiazide Diuretic |
| Physiological Effect | Decreased Renal K+ Excretion Increased Diuresis |
US Patents and Regulatory Information for TRIAMTERENE AND HYDROCHLOROTHIAZIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; triamterene | CAPSULE;ORAL | 074970-001 | Jan 6, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Rubicon | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 216211-002 | Feb 23, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 208360-001 | Jun 29, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
